Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, outlines methods for managing the adverse events (AEs) associated with chimeric antigen receptor T-cell (CAR-T) therapy. For instance, cytokine release syndrome (CRS) can be avoided by using cytokines which slowly activate immune cells and keep them in their early phenotype. Furthermore, in clinical practice CRS can be managed by pre-conditioning patients to suppress their immune system. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
